Characterisation of Fibrinogen Oslo IV by Electrospray Mass Spectrometry

1. van der Meer J. Hillege HL, Koostra GJ, Ascoop CAPL, Pfisterer M, van Gilst WH. Lie KI. Prevention of one-year vein-graft occlusion after aortocoronary bypass surgery: A comparison of low-dose aspirin, low-dose aspirin plus dipyramidole, and oral anticoagulant. Lancet 1993; 342: 257-64. 2. van der Meer J, Hillege HL, Ascoop CAPL, Dunselman PHJM, Mulder BJM, van Ommen GVA, Pfisterer M, van Gilst WH, Lie KI. Aprotinin in aortocoronary bypass surgery: Increased risk of vein-graft occlusion and myocardial infarction? Supportive evidence from a retrospective study. Thromb Haemost 1996; 75: 1-3. 3. Ollivier JP. Permeability of aortocoronary bypass after 6 months. A multicentre French study. Arch Ma1 Coeur Vaiss 1991; 84: 537-42. 4. Cosgrove DM, Heric B, Lytle BW, Taylor PC, Novoa R, Golding LAR, Stewart RW, McCarthy PM, Loop FD. Aprotinin therapy for reoperative myocardial revascularisation: a placebo controlled study. Ann Thorac Surg 1992; 54: 1031-8. 5. Najman DM, Walenga JM, Fareed J. Pifarre R. Effects of aprotinin on anticoagulant monitoring: implications in cardiovascular surgery. Ann Thorac Surg 1993; 55: 662-6. 6. Lass M. Welz A. Kochs M, Mayer G, Schwandt M, Hannekum A. Aprotinin in elective primary bypass surgery. Graft patency and clinical efficacy. Eur J Cardiothorac Surg 1995; 9: 206-10. 7. Bidstrup BP, Underwood SR, Sapsford RN, Streets EM. Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. J Thorac CardiovascSurg 1993; 105: 147-52. 8. Kalangos A, Tapyareci G, Pretre R, Pretre R, Di Dio P, Sezerman 0 . 9. Lemmer JH, Stanford W, Bonney SL. Breen JF, ChomkaEV. Eldredge WJ, Holt WW, Karp RB, Laub GW, Lipton MJ, Schaff HV. Tatooles CJ, Rumberger JA. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Snrg 1994; 107: 543-51. 10. Havel M, Grabenwoger F, Schneider J, Laufer G, Wollenek G, Owen A, Simon P, Teufelsbauer H, Wolner E. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg. 1994; 107: 807-10. 11. Laub GW. Riebman JB, Chen C, Adkins MS, Anderson WA, Fernandez J, McGrath LB. The impact of aprotinin on coronary artery bypass graft patency. Chest;1994; 106: 1370-5. 12. Wendel HP, Heller W. Gallimore MJ, Bantel H, Muller BH. Hoffmeister HE. The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement. Blood Coag Fibrin01 1993; 4: 41-5. 13. Hunt BJ, Segal HC, Yacoub M. Guidelines for monitoring heparin by the activated clotting time when aprotinin is used during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1992; 104: 211-2. 14. DerSimonian R, Laird NM. Meta-analysis in clinical trials. Controlled Clin Trials 1986; 7: 177-88. 15. Underwood MJ, Cooper GJ. Aprotinin and vein graft occlusion after coronary artery bypass. J Thorac Cardiovasc Surg 1995; 109: 1022. 16. van der Meer J, Hillege HL. van Gilst WH, Brute1 de la Rivikre A, Dunselman PHJM. Fidler V. Koostra GJ, Mulder BJM. Pfisterer M, Lie KI. A comparison of internal mammary artery and saphenons vein grafts after coronary artery bypass: no difference in one year occlusion rates and clinical outcome. Circulation 1994; 90: 2367-74. 17. Levy JH, Pifarre R, Schaff HV, Horrow JC, Albus R, Spiess B, Rosengart TK, Murray J, Clark RE, Smith P, Nadel A, Bonney SL, Kleinfield R. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995: 92: 2236-44. Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization. Eur J Cardiothorac Surg 1994; 8: 65 1-56. Received September 9, 1996 Accepted after resubmission January 7, 1997